Joel Pearlman

5.6k total citations · 3 hit papers
30 papers, 3.3k citations indexed

About

Joel Pearlman is a scholar working on Ophthalmology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Joel Pearlman has authored 30 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Ophthalmology, 12 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Joel Pearlman's work include Retinal Diseases and Treatments (15 papers), Retinal and Optic Conditions (9 papers) and Retinal Development and Disorders (7 papers). Joel Pearlman is often cited by papers focused on Retinal Diseases and Treatments (15 papers), Retinal and Optic Conditions (9 papers) and Retinal Development and Disorders (7 papers). Joel Pearlman collaborates with scholars based in United States, Germany and Australia. Joel Pearlman's co-authors include Arun Patel, Robert Wendel, Dante J. Pieramici, Ma'an Nasir, Melvin Rabena, Matthew Giust, Robert L. Avery, Alessandro Castellarin, Peter A. Campochiaro and David S. Boyer and has published in prestigious journals such as Nature, Science and SHILAP Revista de lepidopterología.

In The Last Decade

Joel Pearlman

29 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy

2006 603 citations Joel Pearlman, Robert Wendel et al. Ophthalmology profile →
Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease

2017 350 citations David S. Boyer, Joel Pearlman et al. profile →
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration

2020 307 citations Glenn J. Jaffe, Keith Westby et al. Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Pearlman United States	18	2.0k	1.4k	1.3k	409	231	30	3.3k
Kei Shinoda Japan	33	2.6k 1.3×	1.5k 1.1×	1.5k 1.1×	491 1.2×	130 0.6×	219	3.8k
Keisuke Mori Japan	35	2.2k 1.1×	1.6k 1.1×	1.4k 1.0×	282 0.7×	315 1.4×	133	3.8k
Shigeo Tsukahara Japan	32	2.9k 1.5×	981 0.7×	1.6k 1.2×	248 0.6×	251 1.1×	157	3.9k
Haruki Abe Japan	33	3.3k 1.7×	1.1k 0.8×	2.0k 1.5×	286 0.7×	128 0.6×	126	4.4k
Elliott H. Sohn United States	33	2.7k 1.4×	1.3k 1.0×	1.6k 1.3×	193 0.5×	75 0.3×	102	3.6k
Yasuhiro Ikeda Japan	26	1.5k 0.8×	1.5k 1.1×	712 0.6×	237 0.6×	59 0.3×	104	2.5k
Chan Kee Park South Korea	39	4.2k 2.1×	787 0.6×	2.8k 2.2×	152 0.4×	97 0.4×	214	4.9k
Nahoko Ogata Japan	30	2.0k 1.0×	1.1k 0.8×	1.1k 0.9×	86 0.2×	82 0.4×	145	2.8k
Ray F. Gariano United States	19	938 0.5×	932 0.7×	590 0.5×	486 1.2×	70 0.3×	41	2.0k
Shuichi Yamamoto Japan	30	2.8k 1.4×	1.2k 0.9×	2.0k 1.6×	341 0.8×	69 0.3×	199	3.8k

Countries citing papers authored by Joel Pearlman

Since Specialization

Citations

This map shows the geographic impact of Joel Pearlman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Pearlman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Pearlman more than expected).

Fields of papers citing papers by Joel Pearlman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Pearlman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Pearlman. The network helps show where Joel Pearlman may publish in the future.

Co-authorship network of co-authors of Joel Pearlman

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Pearlman. A scholar is included among the top collaborators of Joel Pearlman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Pearlman. Joel Pearlman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barakat, Mark, David M. Brown, Rahul N. Khurana, et al.. (2024). Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial. SHILAP Revista de lepidopterología. 5(1). 100586–100586. 4 indexed citations

Boyer, David S., Nathan Steinle, Joel Pearlman, et al.. (2024). Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema. Translational Vision Science & Technology. 13(12). 32–32.

Chang, Margaret & Joel Pearlman. (2022). Private equity ownership of ophthalmology practices: how does it impact clinical research?. Current Opinion in Ophthalmology. 33(5). 368–372. 1 indexed citations

Jaffe, Glenn J., Keith Westby, Karl G. Csaky, et al.. (2020). C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration. Ophthalmology. 128(4). 576–586. 307 indexed citations breakdown →

Witkin, André J., Paul Hahn, Timothy G. Murray, et al.. (2020). Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. Journal of VitreoRetinal Diseases. 4(4). 269–279. 137 indexed citations

Witkin, André J., Paul Hahn, Timothy G. Murray, et al.. (2020). Brolucizumab-Associated Intraocular Inflammation in Eyes Without Retinal Vasculitis. Journal of VitreoRetinal Diseases. 5(4). 326–332. 29 indexed citations

Dugel, Pravin U., David S. Boyer, Andrew N. Antoszyk, et al.. (2019). Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 4(3). 250–263. 45 indexed citations

Rosenfeld, Philip J., Pravin U. Dugel, Frank G. Holz, et al.. (2018). Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 125(10). 1556–1567. 95 indexed citations

Gallemore, Ron P., et al.. (2017). Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clinical ophthalmology. Volume 11. 223–231. 12 indexed citations

10.

Jaffe, Glenn J., Thomas A. Ciulla, Antonio P. Ciardella, et al.. (2016). Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration. Ophthalmology. 124(2). 224–234. 114 indexed citations

11.

Pearlman, Joel, et al.. (2015). MULTIFOCAL CHOROIDITIS AND PANUVEITIS PRESENTING WITH PROGRESSIVE EQUATORIAL LINEAR STREAKS. Retinal Cases & Brief Reports. 9(3). 214–217. 8 indexed citations

12.

Campochiaro, Peter A., Raafay Sophie, Joel Pearlman, et al.. (2013). Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab. Ophthalmology. 121(1). 209–219. 261 indexed citations

13.

McDonald, H. Richard, Arthur D. Fu, J. Michael Lahey, et al.. (2010). Unexplained vision loss following removal of epiretinal membrane. British Journal of Ophthalmology. 94(8). 1033–1039. 6 indexed citations

14.

Duh, Elia J., Hoseong S. Yang, Izumi Suzuma, et al.. (2002). Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth.. PubMed. 43(3). 821–9. 248 indexed citations

15.

Pearlman, Joel, et al.. (2002). MORPHOMETRIC ANALYSIS OF THE MACULA IN EYES WITH DISCIFORM AGE-RELATED MACULAR DEGENERATION. Retina. 22(4). 471–477. 122 indexed citations

16.

Mori, Keisuke, Elia J. Duh, Peter Gehlbach, et al.. (2001). Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization. Journal of Cellular Physiology. 188(2). 253–263. 274 indexed citations

17.

Pearlman, Joel, et al.. (1999). Fourth cranial nerve palsy in pediatric patients with pseudotumor cerebri. American Journal of Ophthalmology. 127(2). 236–237. 37 indexed citations

18.

Pearlman, Joel, et al.. (1994). Troponin T is capable of binding dystrophin via a leucine zipper. FEBS Letters. 354(2). 183–186. 18 indexed citations

19.

Fu, Ying‐Hui, David L. Friedman, Stephen Richards, et al.. (1993). Decreased Expression of Myotonin-Protein Kinase Messenger RNA and Protein in Adult Form of Myotonic Dystrophy. Science. 260(5105). 235–238. 249 indexed citations

20.

Lee, Cheng Chi, Joel Pearlman, Jeffrey S. Chamberlain, & C. Thomas Caskey. (1991). Expression of recombinant dystrophin and its localization to the cell membrane. Nature. 349(6307). 334–336. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact